Health Athenex 宣布 Quantum Leap Healthcare Collaborative 報告口服紫杉醇聯合 PD-1 和卡鉑在乳腺癌新輔助治療中的 I-SPY2 試驗結果顯著 James Pereira Dec 21, 2022 紐約水牛城, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX),一家致力於癌症及相關疾病新療法的發現、開發和商業化的全球性生物製藥公司今日宣布,其在… Read More...
Health Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2… James Pereira Dec 20, 2022 BUFFALO, N.Y., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company… Read More...
Health Athenex 退出 503B 無菌復合業務 James Pereira Dec 17, 2022 佈法羅,紐約州, Dec. 17, 2022 (GLOBE NEWSWIRE) -- Athenex,Inc (NASDAQ: ATNX)… Read More...
Health Athenex Exits 503B Sterile Compounding Business James Pereira Dec 16, 2022 BUFFALO, N.Y., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company… Read More...
Health Athenex 宣佈在《Journal of Clinical Oncology》發表比較口服紫杉醇加 Encequidar 與靜脈注射紫杉醇治療轉移性乳癌患者的第 3 期研究數據 James Pereira Jul 26, 2022 紐約水牛城, July 26, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX)… Read More...
Health Athenex 將在 2022 年 7 月 28 日為 2022 年第二季度提供企業及財務更新 James Pereira Jul 22, 2022 紐約水牛城, July 22, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX) 是一家致力於研究與開發用於治療癌症和相關疾病的新療法,並將其商業化的全球生物製藥公司。今天宣佈將在… Read More...
Health Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022 James Pereira Jul 21, 2022 BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated… Read More...
Health Athenex 參與 Truist Securities 細胞治療座談會 James Pereira Jun 24, 2022 紐約水牛城, June 24, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX)是一家全球生物製藥公司,致力發現、開發及商業化旨在治療癌症和相關疾病的新型療法,今天宣佈 Athenex… Read More...
Health Athenex to Participate in Truist Securities Cell Therapy Symposium James Pereira Jun 23, 2022 BUFFALO, N.Y., June 23, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated… Read More...
Health Athenex 將在 SABCS 2021 上發表口服紫杉醇加 Encequidar (KX-ORAX-001) 用於治療轉移性乳癌的第 3 期研究的亞組分析 James Pereira Nov 23, 2021 安全性數據分析表明,肝功能檢查升高的患者發生中性粒細胞減少相關毒性的風險增加 對該肝損傷患者亞組進行了事後分析,結果顯示口服紫杉醇治療的患者中位存活率為 18.9 個月,而靜脈注射紫杉醇治療的患者為 10.1 個月,風險比為 0.59… Read More...